Viridian Therapeutics, Inc./DE Interest Payable, Current
Viridian Therapeutics, Inc./DE (VRDN) had Interest Payable, Current of $595.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2026-08-06
- 2026-06-30: Interest Payable, Current $595.00K.
- 2026-03-31: Interest Payable, Current $385.00K.
- 2025-12-31: Interest Payable, Current $385.00K.
- 2025-09-30: Interest Payable, Current $149.00K.
| Period end | Interest Payable, Current |
|---|---|
| 2026-06-30 | $595.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $385.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $385.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $149.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $149.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $154.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $154.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $149.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $149.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $154.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $154.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $149.00K 10-Q · filed 2023-11-13 |
| 2022-12-31 | $39.00K 10-K · filed 2024-02-27 |
| 2015-09-30 | $50.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $28.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |